## Tumour-associated tryps in inhibitor, carcinoembryonic proteins CRP and $\hat{I}\pm 1$ -antitryps in in patients with gastr

Clinical Biochemistry

37, 56-60

DOI: 10.1016/j.clinbiochem.2003.09.002

**Citation Report** 

ITATION RED

IF

#	Article	IF	CITATIONS
1	Cancer and Inflammation. , 2004, , .		2
2	Nanoprobe-Based Affinity Mass Spectrometry for Selected Protein Profiling in Human Plasma. Analytical Chemistry, 2005, 77, 5990-5997.	6.5	77
3	Ethylene Glycol-Protected Magnetic Nanoparticles for a Multiplexed Immunoassay in Human Plasma. Small, 2006, 2, 485-489.	10.0	140
4	Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. Journal of Pathology, 2006, 209, 147-156.	4.5	125
5	Nanomaterial Based Affinity Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry for Biomolecules and Pathogenic Bacteria. Recent Patents on Nanotechnology, 2007, 1, 99-111.	1.3	27
6	Targeted protein quantitation and profiling using PVDF affinity probe and MALDIâ€TOF MS. Proteomics, 2007, 7, 3038-3050.	2.2	17
7	Serological Proteomics of Gastritis: Degradation of Apolipoprotein A-I and Alpha1-Antitrypsin Is a Common Response to Inflammation Irrespective of Helicobacter pylori Infection. Digestive Diseases and Sciences, 2008, 53, 3112-3118.	2.3	8
8	Multiplexed Immunoassay: Quantitation and Profiling of Serum Biomarkers Using Magnetic Nanoprobes and MALDI-TOF MS. Analytical Chemistry, 2008, 80, 6159-6167.	6.5	77
9	Identification of trypsinâ€inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor. Proteins: Structure, Function and Bioinformatics, 2009, 77, 209-219.	2.6	19
10	Peptidomimetic–functionalized carbon nanotubes with antitrypsin activity. Carbon, 2009, 47, 3550-3558.	10.3	15
11	Can the Acute-Phase Reactant Proteins be Used as Cancer Biomarkers?. International Journal of Biological Markers, 2010, 25, 1-11.	1.8	47
12	Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer, 2010, 10, 498.	2.6	26
13	Alpha-1 Antitrypsin Deficient Squamous Cell Carcinoma of Esophagus in the Azeri Population of Iran. Laboratory Medicine, 2010, 41, 613-618.	1.2	3
14	Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. Radiation Oncology, 2011, 6, 100.	2.7	5
15	Structural Features, Biological Functions of the Alpha-1 Antitrypsin and Contribution to Esophageal Cancer. , 0, , .		3
16	Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker. PLoS ONE, 2013, 8, e59459.	2.5	67
17	TATI as a biomarker. Clinica Chimica Acta, 2014, 431, 260-269.	1.1	33
18	A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of	6.8	42 _

CITATION REPORT

#	Article	IF	CITATIONS
19	Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumor Biology, 2016, 37, 9367-9374.	1.8	8
20	Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia. Experimental Biology and Medicine, 2017, 242, 1363-1375.	2.4	4
21	Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer. Acta Oncológica, 2020, 59, 681-688.	1.8	6
22	Cancer as a chronic inflammatory disease: role of immunotherapy. , 2004, , 21-51.		3
23	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE, 2016, 11, e0165615.	2.5	31
24	Alpha-1 Antitrypsin Blood Levels as Indicator for the Efficacy of Cancer Treatment. World Journal of Oncology, 2013, 4, 83-86.	1.5	9
25	Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ, 2016, 4, e2450.	2.0	17
26	Inflammation, necrosis, and cancer. , 2004, , 189-196.		2
28	Evaluation of TATI marker assays – the pancreatic trypsin inhibitor – in patients with endometrial cancer with unfavorable predictors. Current Gynecologic Oncology, 2013, 11, 103-114.	0.1	0
29	New intracellular and molecular aspects in pathophysiology of colorectal cancer. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 43-52.	0.6	2
30	TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. Oncology, 2022, 100, 22-30.	1.9	3
31	Inâ€situ PLLâ€gâ€PEG Functionalized Nanopore for Enhancing Protein Characterization. Chemistry - an Asian Journal, 2023, 18, .	3.3	1